The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country.

Statement of Results status for the study	
Name of Company: GlaxoSmithKline	
Study No: MVC116278 (EudraCT#2011-004435-31)	
Product: lamivudine; maraviroc; zidovudine; zidovudine/lamivudine	
Title: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc	
Phase: N/A	
Study Period: May 2012 to August 2016	
Centers: 29	
Number of Subjects:120	
Publications: NA	
Statement on results availability: This is an Expanded Access Program and no participant data is expected to be collected. Thus, no study results are expected in this protocol.	